1-4 of 4
Wang Li
Close
Sort by
Journal Articles

Preliminary Results from a Phase I/II Study of Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PRIDE)

Pengpeng Xu, Wang Li, Shu Cheng, Wei Li Zhao
Journal: Blood
Blood (2023) 142 (Supplement 1): 6229.
https://doi.org/10.1182/blood-2023-186087
Published: 2023
Journal Articles

CEBPA Gene Different Mutants Play Distinct Impacts On Tumor Suppressor Function Of C/EBP-Alpha and Bone Marrow Stromal Cells

Haowen Xiao, Wang Li-Mengmeng, Binsheng Wang, Chong Wang, Lifei Zhang, Shan Fu, Yebo Wang, He Huang
Journal: Blood
Blood (2013) 122 (21): 2519.
https://doi.org/10.1182/blood.V122.21.2519.2519
Published: 2013
Journal Articles

Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence

Ayalew Tefferi, MD, Francesco Passamonti, MD, Tiziano Barbui, MD, Giovanni Barosi, MD, Kebede Begna, MD, Mario Cazzola, Francisco Cervantes, MD, PhD, Konstanze Döhner, M.D., Heinz Gisslinger, MD, Vikas Gupta, MD, MRCP, FRCPath, Wang Li, C N Harrison, Jean-Jacques Kiladjian, Mary Frances McMullin, MD, MRCPath, Alessandro Rambaldi, MD, Gary J. Schiller, MD, FACP, Alessandro M Vannucchi, MD, Ruben A. Mesa, MD
Journal: Blood
Blood (2013) 122 (21): 394.
https://doi.org/10.1182/blood.V122.21.394.394
Published: 2013
Journal Articles

PI3K/AKT/mTOR Signaling Is a Significant Druggable Pathway In Infant Acute Lymphoblastic Leukemia (ALL)

Karen A. Urtishak, PhD, Wang Li-San, PhD, David T. Teachey, MD, Tasian K. Sarah, MD, Jeffrey S. Barrett, PhD, I-Ming L. Chen, Susan R. Atlas, PhD, Richard C. Harvey, PhD, Nyla A. Heerema, PhD, Andrew J. Carroll, PhD, Stephen P. Hunger, MD, Cheryl L. Willman, MD, Carolyn A. Felix, MD
Journal: Blood
Blood (2013) 122 (21): 1669.
https://doi.org/10.1182/blood.V122.21.1669.1669
Published: 2013